Suanfarma Suanfarma

X
[{"orgOrder":0,"company":"Farmalider SA","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo Laboratories, Inc. Acquires International Rights to Sildenafil Oral Spray for the Treatment of Erectile Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Farmalider SA

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Aspargo’s Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump (referred to as ASP-001) or via an individual single liquid unit dispensing 100 mg per unit.

            Lead Product(s): Sildenafil Citrate

            Therapeutic Area: Endocrinology Product Name: Viagra

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Aspargo Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition September 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY